Natera to Present New MRD Data on Multiple Tumors at ASCO Meeting

Natera Inc. (NASDAQ: NTRA), headquartered in Austin, Texas, a prominent player in cell-free DNA and genetic testing, has announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 31 to June 4, 2024. The company, in collaboration with its partners, will unveil new findings across several cancer types, including breast cancer, colorectal cancer (CRC), lung cancer, melanoma, esophageal cancer, and urothelial cancer.

Key among the presentations is data on Natera's Signatera™, a personalized, tumor-informed molecular residual disease (MRD) test, which features in one oral presentation and 12 poster presentations. Additionally, there will be a poster presentation on Empower™, Natera’s hereditary cancer test.

Minetta Liu, MD, Natera's chief medical officer of oncology, expressed anticipation over sharing these new findings, emphasizing that they reflect Natera's extensive clinical research in MRD. Highlighted among the new data are results from the CIRCULATE-Japan GALAXY study, which showcase the prognostic and predictive capabilities of Signatera and its actionable biomarkers in colorectal cancer.

The GALAXY study is a segment of the larger CIRCULATE-Japan trial framework, which also includes ALTAIR, a pioneering study examining the utility of Signatera in CRC by initiating treatment based on molecular recurrence. Natera plans to release topline results from this phase III randomized trial in August 2024.

The detailed agenda of the ASCO presentations includes the following significant studies:

1. Poster Presentation: Abstract #3609, presented by Dr. Yoshiaki Nakamura, highlights the prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable CRC as part of the CIRCULATE-Japan GALAXY study.

2. Oral Presentation: Abstract #LBA507 by Dr. Sherene Loi, discusses the prognostic utility of ctDNA dynamics in the monarchE trial for patients with high-risk early breast cancer.

3. Poster Presentation: Abstract #3586, presented by Dr. Eric Lander, examines genomic differences between early-onset and average-onset stage IV CRC.

4. Poster Presentation: Abstract #5034 by Dr. Rebecca Hassoun, evaluates ctDNA as a prognostic biomarker for detecting minimal residual disease in testicular cancer.

5. Poster Presentation: Abstract #4587, presented by Dr. Adanma Ayanambakkam, involves the longitudinal analysis of ctDNA in localized and metastatic urothelial cancer.

6. Poster Presentation: Abstract #4028, presented by Dr. Aziz Zaanan, explores ctDNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma.

7. Poster Presentation: Abstract #9564 by Dr. Michael LaPelusa, links ctDNA levels to recurrence-free survival in patients with resected stage III melanoma.

8. Poster Presentation: Abstract #6056, presented by Dr. Glenn Hanna, examines the use of personalized ctDNA monitoring in HPV-negative head and neck squamous cell carcinoma.

9. Poster Presentation: Abstract #TPS8659 by Dr. Yasushi Goto, describes a phase III study on PD-1 pathway blockade in advanced non-small-cell lung cancer.

10. Poster Presentation: Abstract #569, presented by Dr. Mridula George, predicts responses to neoadjuvant therapy in early-stage breast cancer using ctDNA testing.

11. Poster Presentation: Abstract #549 by Dr. Marla Lipsyc-Sharf, investigates the impact of ctDNA surveillance on clinical care for stage I-III breast cancer.

12. Poster Presentation: Abstract #518, presented by Dr. Yoichi Naito, reports interim findings on ctDNA monitoring for high risk recurrent breast cancer.

13. Poster Presentation: Abstract #10596 by Dr. Sarah Lee, focuses on Empower, highlighting the utility of a targeted panel of high-risk hereditary cancer genes.

About Signatera: Signatera is a custom-built, tumor-informed MRD test utilizing circulating tumor DNA to detect residual cancer, anticipate recurrence, and guide treatment decisions. It is available for clinical and research purposes and covered by Medicare for several cancers, including colorectal, breast, ovarian, and muscle invasive bladder cancers, as well as for immunotherapy monitoring of solid tumors. Signatera has been validated in over 60 peer-reviewed publications.

About Natera: Natera specializes in cell-free DNA and genetic testing across oncology, women’s health, and organ health, striving to integrate personalized genetic testing into standard care. Their tests' efficacy is supported by more than 200 peer-reviewed publications. Natera operates ISO 13485-certified and CAP-accredited labs in Austin, Texas, and San Carlos, California.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!